Outlook Therapeutics, Inc.

OTLK · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders12.6%

Institutions16.7%

Public / Other

Income Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	$1.41M	–	–	–	–	–	$8.15M	$3.09M	$3.81M	$2.98M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$1.36M	–	–	–	–	–	–	–	–	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$57205	–	–	–	–	–	–	–	–	–
Gross profit as a percentage of revenue.	4.0%	–	–	–	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$67.06M	-$71.70M	-$53.13M	-$63.07M	-$51.73M	-$36.84M	-$36.30M	-$29.64M	-$35.88M	-$51.76M
Operating income as a percentage of revenue.	-4744.3%	–	–	–	–	–	-445.6%	-960.1%	-941.4%	-1737.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$62.42M	-$75.37M	-$58.98M	-$66.05M	-$53.16M	-$35.24M	-$34.52M	-$30.09M	-$38.85M	-$53.33M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.79	$-4.06	$-0.24	$-0.31	$-0.35	$0.00	$-1.00	$-1.00	$-1.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.79	$-4.00	$0.00	$0.00	$-0.35	–	–	$-1.00	$-1.00	–

Balance Sheet

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Cash and highly liquid short-term investments the company can access almost immediately.	$8.08M	$14.93M	$23.39M	$17.40M	$14.48M	$12.54M	$8.02M	$1.72M	$3.19M	$2.35M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$18.58M	$28.82M	$32.30M	$28.53M	$22.81M	$19.73M	$17.13M	$22.28M	$20.73M	$23.71M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	$1.08M	$4.78M	$4.82M	$7.43M
Everything the company owes — debt, unpaid bills, and other obligations.	$50.77M	$101.90M	$46.74M	$19.79M	$18.20M	$16.91M	$27.90M	$43.09M	$51.46M	$28.91M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$32.19M	-$73.08M	-$14.44M	$8.74M	$4.61M	$2.83M	-$16.13M	-$25.54M	-$33.65M	-$5.20M

Cash Flow Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$51.83M	-$68.79M	-$42.97M	-$56.67M	-$54.25M	-$31.79M	-$32.29M	-$33.04M	-$15.51M	-$45.48M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	–	–	–	$437307	$2.78M	$292086	$1.10M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	–	–	–	-$32.73M	-$35.82M	-$15.80M	-$46.58M

	You	Peer avg
Revenue Growth	-99.4%	-4.4%
ROE	–	-262.5%

Outlook Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison